Stockscreener 앱 받기
1.35
1.83%
-0.0252
전일 마감가:
$1.3752
열려 있는:
$1.34
하루 거래량:
5,125
Relative Volume:
0.26
시가총액:
$60.37M
수익:
$118.18M
순이익/손실:
$5.99M
주가수익비율:
10.24
EPS:
0.1319
순현금흐름:
$-12.91M
1주 성능:
+5.47%
1개월 성능:
-9.40%
6개월 성능:
-21.97%
1년 성능:
-46.64%
1일 변동 폭
$1.33
$1.38
1주일 범위
$1.29
$1.38
52주 변동 폭
$1.17
$3.72
Intercure Ltd Stock (INCR) Company Profile
INCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
1.35 | 60.37M | 118.18M | 5.99M | -12.91M | 0.1319 |
|
ZTS
Zoetis Inc
|
146.85 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.19 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.31 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.25 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-05-18 | 업그레이드 | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd 주식(INCR)의 최신 뉴스
InterCure (NASDAQ:INCR) Stock Price Down 3.4% – Time to Sell? - Defense World
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - GuruFocus.com
InterCure (NASDAQ:INCR) Shares Down 0.7%What's Next? - MarketBeat
InterCure Announces Leadership Change and Secures $18.2 Million Financing - TipRanks
Short Interest in InterCure Ltd. (NASDAQ:INCR) Expands By 96.2% - MarketBeat
Jane Street Group LLC Acquires New Stake in InterCure Ltd. (NASDAQ:INCR) - Defense World
InterCure (NASDAQ:INCR) Trading Up 3.7% – Should You Buy? - Defense World
Cannabis co InterCure raising NIS 66m for Nir Oz facility - Globes
InterCure secures $18.2M for post-war recovery By Investing.com - Investing.com Australia
InterCure secures $18.2M for post-war recovery - Investing.com
InterCure Secures Major Funding to Boost Growth - TipRanks
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - Nasdaq
Reviewing InterCure (NASDAQ:INCR) & NeuroBo Pharmaceuticals (NASDAQ:NRBO) - Defense World
InterCure Ltd. (NASDAQ:INCR) Short Interest Update - MarketBeat
InterCure Ltd. (NASDAQ:INCR) Sees Significant Drop in Short Interest - MarketBeat
Synbiotic's CAGR Forecast at 80%, ECS Botanics to Expand Footprint in Germany, & More from Intercure - Business of Cannabis -
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
InterCure nears break even in first half of 2024, despite ongoing Israel-Hamas war - Green Market Report
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewswire
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Yahoo Finance
Cannabis News: Majority of Americans Want Rescheduling or Legalization; European Market Growth Could be Game-Changer; Spotlight on InterCure - Market Research Record
IM Cannabis Merger Scrapped, Cel AI Gets a New CEO, & More from Intercure - Business of Cannabis
Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ - Benzinga
Analyst: Israel’s InterCure paving path to big gains - Green Market Report
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference - Business Wire
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million - Business Wire
InterCure: Bargain Israel Cannabis Play (NASDAQ:INCR) - Seeking Alpha
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint - Business Wire
InterCure Provides Update Regarding Nir Oz Facility in Israel - Cannabis Business Times
InterCure Provides an Update Regarding Nir Oz Facility - GlobeNewswire
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain - GlobeNewswire
InterCure Wins Cannolam Arbitration Proceeding - GlobeNewswire
Israeli Cannabis Firms Navigate Challenges Amid Hamas Conflict, Cellular Goods Signs New Joint Venture, & More from SEED Innovations - Business of Cannabis -
InterCure Ltd Issues Update Regarding the Security Situation in Israel By Investing.com - Investing.com UK
Israeli Cannabis Adjusts to War - Green Market Report
Celadon Announces New £1.2m Supply Deal, Intercure Continues Record Run, & Chill Brands Launches Products in UK - Business of Cannabis -
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY - GlobeNewswire
InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE - Stock Titan
Cookies launches flagship store in Austria with InterCure - Business of Cannabis -
Intercure Counter-Sued By Better, Cantourage Sees Stock Jump 30%, & Tikun Olam Cannbit To Be Acquired - Business of Cannabis -
InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary - Stock Titan
InterCure to distribute Mike Tyson’s cannabis internationally - Mugglehead Magazine
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries - GlobeNewswire
InterCure Delivers Rising Revenue, Positive Cash Flow - Green Market Report
InterCure Ltd. - Baystreet.ca
InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better) - GlobeNewswire
InterCure: Why The Company Is Grossly Undervalued By Wall Street - Seeking Alpha
InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske" - GlobeNewswire
Intercure Ltd (INCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
0.69%
자본화:
|
볼륨(24시간):